Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
3
60%
Ph phase_2
2
40%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

terminated120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Effects of HQK-1001 in Patients With Sickle Cell Disease

NCT01601340
completedphase_2

A Study of HQK-1001 in Patients With Sickle Cell Disease

NCT01322269
completedphase_1

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

NCT00842088
completedphase_1

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

NCT00790127
completedphase_1

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

NCT00717262

Clinical Trials (5)

Showing 5 of 5 trials
NCT01601340Phase 2

Effects of HQK-1001 in Patients With Sickle Cell Disease

Terminated
NCT01322269Phase 2

A Study of HQK-1001 in Patients With Sickle Cell Disease

Completed
NCT00842088Phase 1

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Completed
NCT00790127Phase 1

Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia

Completed
NCT00717262Phase 1

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5